Form 4: MiNK Therapeutics Director Acquires Shares via RSU Grant

MiNK Therapeutics Director Robert Peter Kadlec acquired 975 shares of common stock through restricted stock units as part of his board and committee compensation.

Summary

• Robert Peter Kadlec, a Director of MiNK Therapeutics, Inc. (INKT), acquired 975 shares of common stock.
• The acquisition occurred on September 2, 2025, at a price of $13.86 per share.
• These shares were granted as Restricted Stock Units (RSUs) in lieu of cash retainers for board and committee compensation.
• The RSUs represent a contingent right to receive one share of Common Stock for each RSU and will vest one month from the grant date.
• Following this transaction, Mr. Kadlec beneficially owns 17,908 shares of common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a director acquiring shares, even as compensation, can be interpreted as a sign of confidence. However, it's a routine compensation event rather than an open market purchase, limiting the strength of the positive signal.

Positives

• A director acquiring shares, even as compensation, can signal confidence in the company's future prospects.
• The use of equity (RSUs) for compensation aligns the director's interests with those of shareholders.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction related to director compensation and does not provide broader industry context or trends. Such equity-based compensation is a common practice across various industries to align management and board interests with shareholders.

Related Party Transactions

• The grant of 975 Restricted Stock Units (RSUs) to Director Robert Peter Kadlec in lieu of cash retainers for board and committee compensation constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's increased equity stake as a positive signal of alignment with shareholder interests and confidence in the company's future.

Next Steps

• The 975 Restricted Stock Units (RSUs) are expected to vest approximately one month from the grant date of September 2, 2025.

Key Dates

Keywords

MiNK Therapeutics, INKT, Robert Peter Kadlec, Director, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Equity Compensation, Beneficial Ownership